---
title: "China Resources Pharmaceutical: JZYY achieved a net profit of 307 million yuan in the first quarter, a year-on-year increase of 6.15%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/237733359.md"
description: "According to the Zhitong Finance APP, China Resources Pharmaceutical announced the performance of JZYY for the three months ending March 31, 2025, with total operating revenue of 1.184 billion yuan, a year-on-year decrease of 7.03%; net profit of 307 million yuan, a year-on-year increase of 6.15%"
datetime: "2025-04-28T00:08:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/237733359.md)
  - [en](https://longbridge.com/en/news/237733359.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/237733359.md)
generator: "portal-rs"
---

# China Resources Pharmaceutical: JZYY achieved a net profit of 307 million yuan in the first quarter, a year-on-year increase of 6.15%

According to the Zhitong Finance APP, China Resources Pharmaceutical (03320) released the performance report of JZYY for the three months ending March 31, 2025, with total operating revenue of 1.184 billion yuan, a year-on-year decrease of 7.03%; net profit of 307 million yuan, a year-on-year increase of 6.15%

### Related Stocks

- [600750.CN](https://longbridge.com/en/quote/600750.CN.md)
- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)

## Related News & Research

- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)
- [Trump announces Medicaid drug pricing deals with 9 firms](https://longbridge.com/en/news/297557074.md)
- [Tezos to Launch Post-Quantum Testnet in September](https://longbridge.com/en/news/297946567.md)
- [Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President](https://longbridge.com/en/news/297630906.md)
- [Peab wins SEK 111 million contract to build Torsby central kitchen](https://longbridge.com/en/news/297738524.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**